Randomised Clinical Trial of Adjuvant Chemotherapy in Patients with Node-Negative, Fast-Proliferating Breast Cancer

Paradiso, Angelo; Mangia, Anita; Barletta, A.; Catino, A.; Giannuzzi, A. L.; Schittulli, F.; Radogna, N.; Longo, Salvatore; Palmieri, Dario; Marzullo, F; Natale, Claudia De; Tardio, B; Lena, M. De

doi:10.2165/00003495-199300452-00011

Cited by 9 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the biological factors of clinical relevance as prognostic indicators or predictors of response to clinical treatment, cell kinetics holds a prominent role and has already begun to be utilized as a tool to identify node‐negative breast cancer patients at risk who are candidates for systemic treatment ( Amadori, Volpi & Callea 1993, Paradiso et al 1993 , Hutchins et al 1998 ). Different techniques have been proposed to assess cell proliferation activity, among which the most frequently investigated for basic and clinical studies are [ 3 H]thymidine labelling index ([ 3 H]dT LI), flow cytometric S phase cell fraction (FCM‐S) and Ki‐67 immunoreactivity (Ki‐67/MIB‐1) in accordance with the specific interests of different countries.…”

Section: Introductionmentioning

confidence: 99%

Comparison between differentcell kinetic variables in human breast cancer

et al. 2000

View full text Add to dashboard Cite

Cell kinetics holds a prominent role among biological factors in predicting clinical outcome and response to treatment in neoplastic patients. Different cell kinetic variables are often considered as valid alternatives to each other, but the limited size of case series analysed in several studies and the lack of simultaneous determinations of all the variables on the same tumours do not justify this conclusion. In the present study, the correlation between [3H]thymidine labelling index ([3H]dT LI), flow cytometric S phase cell fraction (FCM-S) and Ki-67 immunoreactivity (Ki-67/MIB-1) was verified and the type of correlation with the most important clinical, pathological and biological patient and tumour characteristics was investigated in a very large series of breast cancer patients. Ki-67/MIB-1, FCM-S and [3H]dT LI were determined in 609, 526 and 485 patients, respectively, and all three cell proliferation indices were evaluated in parallel on the same tumour in a series of 330 breast cancer patients. All the cell kinetic determinations were performed within the context of National Quality Control Programmes. Very poor correlation coefficients (ranging from 0.37 to 0.18) were observed between the different cell kinetic variables determined in parallel on the same series of breast cancers. Moreover, Ki-67/MIB-1 and FCM-S showed a significant relationship with histological type, grade and tumour size, whereas statistically significant correlations were not observed for [3H]dT LI. In conclusion, the results show that the different cell kinetic variables provide different biological information and cannot be considered as alternatives to each other.

show abstract

Section: Introductionmentioning

confidence: 99%

Comparison between differentcell kinetic variables in human breast cancer

et al. 2000

View full text Add to dashboard Cite

show abstract

“…The estimation of TLI, which is generally cumbersome, has been extremely simplified by the availability of a kit for the first methodological steps, and reproducibility of the results is guaranteed by activation and maintenance of quality-control programs in Italy. Notwithstanding difficulties in routinely introducing TLI as part of a prognostic profile on breast cancer, based on consistent results from basic and clinical analyses, prospective multicentric clinical trials have been activated in Italy on node-negative breast cancers in which candidates for adjuvant chemotherapy are selected on the basis of TLI (Amadori et al, 1997;Paradiso et al, 1993). The prognostic and predictive information provided by TLI could represent a translational frame for including in research treatment protocols tumour proliferation indices, which need to be prospectively validated.…”

Section: Clinical Outcome As a Function Of Tli By Treatment Regimenmentioning

confidence: 99%

Cell proliferation and outcome following doxorubicin plus CMF regimens in node‐positive breast cancer

et al. 2000

View full text Add to dashboard Cite

“…Moreover, it is hoped that, as for some biological factors in other human tumour types (Paradiso et al, 1993;Amadori et al, 1994), predictors of response to different systemic treatments will also be identified in lung cancer. DNA ploidy, cell proliferation, and products of oncogenes or tumour-suppressor genes in lung cancer have been extensively investigated (Volm et al, 1985;Alama et al, 1990;Isobe et al, 1990;Miyamoto et al, 1991;Silvestrini et al, 1991;Tungekar et al, 1991;Filderman et al, 1992;McLaren et al, 1992;Quinlan et al, 1992;M0rkve et al, 1993;Scagliotti et al, 1993;Ebina et al, 1994;Passlick et al, 1994).…”

mentioning

confidence: 99%